A llogeneic blood transfusion (ABT) results in the infusion into the recipient of large amounts of foreign antigens, in both soluble and cell-associated forms. The persistence of these antigens in the circulation of the recipient may create conditions that allow for the development of immune down-regulation. Evidence from a variety of sources indicates that ABT enhances the survival of renal allografts (1) and may increase the recurrence rate of resected malignancies (2) and the incidence of postoperative bacterial infections (3) (4) (5) (6) (7) (8) as well as reduce the recurrence rate of Crohn's disease (9) and/or activate infections with cytomegalovirus or HIV (10) . This syndrome, the mechanisms and clinical relevance of which still remain to be defined, has been referred to in the transfusion medicine literature as ABT-related immunomodulation (TRIM) (11, 12) .
Different biological mechanisms may be involved in each purported clinical manifestation of TRIM (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) , and the clinical evidence supporting each of the aforementioned hypotheses (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) should be examined on its own merits. Four possible mechanisms have been postulated to underlie the apparent association of ABT with postoperative bacterial infection (13) . These are a) TRIM effects mediated by immunologically active allogeneic white blood cells (WBCs) that down-regulate the recipient's immune function, thereby predisposing to infection (14 -17) ; b) TRIM effects mediated by soluble biological response modifiers (18) released in a time-dependent manner from WBC granules (19, 20) or membranes (21) into the supernatant fluid of red-blood-cell (RBC) or platelet concentrates during storage; c) TRIM effects mediated by soluble human leukocyte antigen (HLA) peptides or other soluble mediators that circulate in allogeneic plasma (22) (23) (24) ; and d) a possibly non-TRIM effect of ABT, whereby ABT might cause postoperative multiple organ failure (25) (26) (27) (28) ) that might in turn predispose to infection.
Sixteen randomized controlled trials (RCTs) and approximately 40 observational studies have investigated the possibility of an association between perioperative ABT and postoperative infection, including pneumonia (11, 12) . This review categorizes RCTs and observational studies with regard to the inference that they permit about possible mediators of TRIM-allogeneic WBCs, WBC-derived soluble mediators, and/or allogeneic plasma-and examines whether the totality of the clinical evidence supports an association between ABT and postoperative infection. Because the focus is on the totality of the evidence, findings from meta-analyses of the primary studies are reviewed in detail.
All RCTs and virtually all observational studies recorded the occurrence of postoperative pneumonia, along with surgical-site (i.e., wound) infection, bacteremia/septicemia, and/or urinary tract infection and infection at other sites. However, the results of most studies were reported in the aggregate (as number of patients developing postoperative infec-tion at any site), without a breakdown showing the number of site-specific infections recorded in each comparison arm. Accordingly, meta-analyses of the risk of postoperative pneumonia in association with ABT cannot be undertaken, because data on postoperative pneumonia have not been made available in the reports of all studies. Based on the assumption that any mechanism relating ABT to postoperative infection at any site would relate ABT to postoperative pneumonia as well, this review focuses on the association of ABT with postoperative infection at any site. Moreover, the focus is on postoperative infection, because the possibility of TRIM effects outside the perioperative setting has not, hitherto, been adequately studied.
RCTs Investigating the Association of ABT with Postoperative Infection
The specific constituents of allogeneic blood that mediate the TRIM effects remain unknown. Both the animal and human data suggest that the TRIM effects are most likely mediated by transfused allogeneic WBCs and, if this is indeed the case, the TRIM effects should be abrogated if universal WBC reduction of all transfused cellular blood components is introduced. Ten RCTs were designed based on the assumption that the ABT effect that leads to postoperative infection is mediated specifically by allogeneic WBCs. These studies (3, 5-8, 29 -33) produced contradictory findings ( Fig. 1) , and the question whether any deleterious TRIM effects are lessened or abrogated by WBC reduction remains unresolved (34 -39) .
The ten RCTs (3, 5-8, 29 -33) (45) .
A meta-analysis of the five RCTs (4, 41-44) that compared recipients of autologous and allogeneic RBCs or whole blood found no increase in the risk of postoperative infection in association with the transfusion of allogeneic (compared with autologous) blood (45) . RCTs that compared recipients of non-WBCreduced and WBC-reduced allogeneic RBCs could not be integrated in a metaanalysis (40) , because the hypothesis of homogeneity of effects was rejected across these studies (46) . Studies can be combined in a meta-analysis only if the variation in their results is sufficiently modest to be attributed to chance (46) . In the case of the RCTs comparing recipients of non-WBC-reduced and WBCreduced RBCs, the variation in the results of the studies ranged from a 7.3-fold in- (Table 1) , as calculated from an intention-to-treat analysis. Each OR is surrounded by its 95% confidence interval (CI). If the 95% CI of the OR includes the null value of 1, the transfusion-related immunomodulation effect is not statistically significant (p Ͼ .05). A deleterious effect of ABT is indicated by an ORϾ1, provided that the associated 95% CI does not include the null value of 1. crease in the risk of infection (3) to no adverse effect (29 -33) These six RCTs (6, 8, 29 -32 ) enrolled a total of 3,507 patients ( Table 1 ). The hypothesis of homogeneity was not rejected across the studies, and-when the findings of five of the studies (6, 8, 29 -31) were integrated in a meta-analysis-no adverse TRIM effect was detected (summary odds ratio [ (40) . The RCT of van Hilten et al. (32) was reported after the publication of the meta-analysis (40) . In this large RCT (32) , the OR of postoperative infection was 1.0 (95% CI, 0.7-1.3), indicating that recipients of buffy-coat-reduced and WBC-reduced allogeneic RBCs had an identical risk of developing postoperative infection.
Four RCTs (3, 5-7) transfused allogeneic RBCs or whole blood filtered after storage to the control arm and buffycoat-reduced or unmodified RBCs or whole blood to the treatment arm ( Table  1 ). The hypothesis of homogeneity was not rejected across the studies, andwhen their findings were integratedthere was a greater than two-fold increase in the risk of infection in association with the receipt of non-WBC-reduced (com- Table 1 ). The hypothesis of homogeneity was not rejected across the studies, andwhen their findings were integratedthere was an almost two-fold increase in the risk of infection in association with the receipt of nonbuffy-coat-reduced (compared with WBC-reduced) allogeneic RBCs or whole blood (summary OR, 1.77; 95% CI, 1.02-3.09; p Ͻ .05) (40) . This finding would be consistent with a TRIM effect attributed to immunologically active allogeneic WBCs as well as a TRIM effect ascribed to WBC-derived soluble mediators that accumulate during storage.
Two recent RCTs that are available only in abstract form (33, 47) also transfused nonbuffy-coat-reduced allogeneic RBCs to the treatment arm. These RCTs did not observe an increased risk of infection in association with the receipt of nonbuffy-coat-reduced (compared with WBC-reduced) allogeneic RBCs. Thus, the finding of the earlier meta-analysis (40) may have been due to the bias introduced by the inclusion of the study of Jensen et al. (3) . That early RCT (3) had significant methodological limitations (11, 12) , and it reported an unusually large (7.3-fold) increase in the risk of infection in association with the receipt of nonbuffy-coat-reduced (compared with poststorage-filtered WBC-reduced) allogeneic whole blood.
By the time of the meta-analysis (40), three RCTs (6, 8, 31) , transfusing buffycoat-reduced or nonbuffy-coat-reduced allogeneic RBCs to the treatment arm and WBC-reduced RBCs filtered before or after storage to the control arm, had been conducted in the setting of cardiac surgery ( Table 1 ). The hypothesis of homogeneity was not rejected across the studies, and-when their findings were integrated-there was a 39% increase in the risk of infection in association with the receipt of non-WBC-reduced (compared with WBC-reduced) allogeneic RBCs (summary OR, 1.39; 95% CI, 1.08 -1.80; p Ͻ .05) (40) . This TRIM effect may be no longer evident following the reporting of the two recent RCTs (33, 47) , because both of these studies enrolled patients undergoing cardiac surgery and observed no increased risk of infection in association with the receipt of non-WBCreduced (compared with WBC-reduced) RBCs. A formal meta-analysis of all five RCTs (6, 8, 31, 33, 47) that are available presently from the setting of cardiac surgery cannot yet be undertaken, because an intention-to-treat analysis of the results of the latest RCT (47) has not yet been presented.
This author knows of only one RCT (31) whose design permitted the investigators to examine the hypothesis that soluble HLA (or other) molecules circulating in allogeneic plasma may mediate TRIM effects. Wallis et al. (31) randomized 597 patients undergoing cardiac surgery to receive plasma-reduced, buffycoat-reduced, or WBC-reduced allogeneic RBCs. The highest risk of infection was observed in the (WBC-containing) plasma-reduced arm, in which the incidence of postoperative infection was 17.1%, compared with 10.8% in the buffy-coatreduced arm and 11.3% in the WBCreduced arm (p ϭ .20). Thus, plasma removal did not confer any benefit with regard to the prevention of TRIM effects.
Observational Studies Investigating the Association of Allogeneic Blood Transfusion with Postoperative Pneumonia
Approximately 40 observational studies have compared the risk of postoperative bacterial infection between transfused and nontransfused patients undergoing gastrointestinal surgery, orthopedic operations, cardiac surgery, or various other procedures. These studies tended to indicate that patients needing transfusion (compared with those not needing transfusion) almost always had a higher risk of developing postoperative bacterial infection (48) . The studies also indicated that patients receiving transfusion generally differed from those not receiving transfusion in several prognostic factors, including risk factors for the development of postoperative urinary tract infection, pneumonia, or wound infection (49) . These two sets of observations have led to different interpretations of the results of the studies.
Some authors concluded that ABT has a direct deleterious effect on the recipient, causing an increased risk of postoperative bacterial infection (48) . Other investigators concluded that ABT can be a surrogate marker for a variety of adverse prognostic factors and that the other variables that generated the need for ABT in the published studies also determined the subsequent clinical outcome (49) . This latter school of thought reasoned that the adverse prognostic factors that were associated with both the need for ABT and the development of postoperative bacterial infection were confounders of the association between ABT and infection, thus engendering a spurious association between ABT and postoperative bacterial infection (49) . Until recently, observational studies reporting an association between ABT and postoperative infection had not adjusted statistically for the effects of physiologic severity of underlying illness and/or risk factors for postoperative infection at specific sites (11, 12) .
Because these observational studies were comparing transfused and nontransfused patients, they could not point to any specific mediator of TRIM effectsthat is, allogeneic WBCs, WBC-derived soluble mediators, and/or allogeneic plasma. Focusing on the development of postoperative pneumonia (as opposed to postoperative infection at any site), Vamvakas and Carven (50 -52) conducted observational studies whose purpose was to investigate possible mechanisms of TRIM: effects of allogeneic WBCs, WBCderived soluble mediators, and/or allogeneic plasma (13) . Of 416 patients undergoing coronary artery bypass graft operations in their patient population, 256 (61%) were exposed to allogeneic WBCs in units of non-WBC-reduced, allogeneic RBCs and/or platelets, and 274 (65.9%) were exposed to allogeneic plasma in units of allogeneic RBCs, platelets, fresh frozen plasma, and/or cryoprecipitate. Clinical diagnoses of postoperative pneumonia were made in 54 (13.0%) patients. Fifty-one (12.3%) patients were ventilated for Ͼ24 hrs (50 -52) .
Following adjustment for the effects of confounding factors (including variables related to physiologic severity of underlying illness and specific risk factors for postoperative pneumonia), there was an association between the risk of postoperative pneumonia and the length of stor-age of the transfused RBCs (50) . The association between the risk of pneumonia and the number of transfused WBCcontaining allogeneic RBCs and/or platelets did not attain statistical significance (50) . There was no association between the volume of transfused allogeneic plasma and the risk of pneumonia (51). Moreover, there was no association between the number (or length of storage) of transfused WBC-containing allogeneic RBCs and the likelihood of mechanical ventilation past the day of operation-a variable used in this analysis (52) as an indicator of pulmonary failure.
More specifically, in the univariate analyses, 44 (17.2%) patients exposed to allogeneic WBCs developed pneumonia, compared with ten (6.2%) unexposed patients (p ϭ .0009) (50) . The mean (ϮSE) length of storage of RBC units given to patients who developed pneumonia was 15.1 (Ϯ1.3) days; the mean length of storage of RBC units given to those who did not develop pneumonia was 12.3 (Ϯ0.5) days (p ϭ .0306). The mean (ϮSE) length of storage of the longest-and second longest-stored RBC units given to patients who developed pneumonia was 21.3 (Ϯ1.7) days; the corresponding mean (ϮSE) for patients who did not develop pneumonia was 15.6 (Ϯ0.8) days (p ϭ .0018) (50) .
Following adjustment for the effects of confounding factors, the association between postoperative pneumonia and the number of transfused, non-WBC-reduced, allogeneic RBCs and/or platelets was no longer significant (p ϭ .0584). In contrast, following similar adjustment for the effect of confounders, the mean length of storage of all transfused RBCs and the mean length of storage of the longest-and second longest-stored RBC units were significant (p ϭ .0052 and p ϭ .0026, respectively) predictors of the development of postoperative pneumonia (50) .
In the subsequent univariate analysis, the volume of transfused allogeneic plasma differed between patients who did (or did not) develop pneumonia. The former group received (mean Ϯ SE) 1045.7 Ϯ 209.9 mL of allogeneic plasma; the latter group received 325.5 Ϯ 38.8 mL (p Ͻ .001). However, following adjustment for the effects of confounding factors, the volume of transfused allogeneic plasma was no longer associated with postoperative pneumonia (p ϭ .21) (51).
When the association between ABT and postoperative ventilation was examined, there was an overall difference (p Ͻ .0001) in the number of transfused RBCs between five groups of patients who were kept on ventilation for 0, 1, 2, 3, or Ն4 days past the day of operation. Those extubated on the day of operation received (mean Ϯ (52).
Thus, the findings from this cohort of 416 patients suggest that WBC-derived soluble mediators most likely underlie a TRIM effect that perhaps leads to an association between WBC-containing ABT and postoperative pneumonia. Because such substances accumulate in the supernatant fluid of stored RBCs in a timedependent manner, their level (and thus the potential for adverse TRIM effects) increases with increasing length of storage of the transfused RBCs. However, findings from RCTs have not hitherto supported this hypothesis. As already discussed, the adverse TRIM effect appeared to be prevented by transfusion of poststorage-filtered WBC-reduced allogeneic RBCs, whereas prestorage-filtered components devoid of WBC-derived soluble mediators did not appear to confer any benefit (40) . In the RCT of van de Watering et al. (6) , patients randomized to receive prestorage-filtered or poststorage-filtered WBC-reduced allogeneic RBCs had an identical risk of infection.
In addition to the study of Vamvakas and Carven (50), three more observational studies (53) (54) (55) reported an association between prolonged storage of transfused RBCs and increased risk of infection following surgery or injury. This association, however, can also be attributed to the increased rigidity and oxygen affinity of the stored RBCs (56, 57) and/or the progressive depletion of nitric oxide (58) that occurs during RBC storage. Transfusion of stored, rigid RBCs depleted of nitric oxide might impede blood flow to the viscera (through blockage and/or vasoconstriction) and predispose patients to visceral ischemia and, perhaps, infection. Such a deleterious effect of "old" blood would not be affected by WBC reduction of RBC components and could be abrogated only by limiting the allowed length of storage of transfused RBCs. Leal-Noval et al. (55) reported that RBC storage for Ͼ28 days may be a risk factor for developing postoperative pneumonia.
Groce et al. (59) found that transfusion during trauma resuscitation was associated with the development of pneumonia. Shorr et al. (60) focused on the development of ventilator-associated pneumonia (VAP) in an analysis of 1,518 patients who had undergone mechanical ventilation for at least 48 hrs. (These patients were a subset from a large, multicenter observational study that had included patients from 284 intensive care units in the United States.) Following adjustment for the effects of confounding factors, RBC transfusion was independently associated with VAP (p Ͻ .005), and patients receiving more than two RBC units were more than twice as likely to develop VAP. Although the authors did not state whether the RBC units were WBC-reduced, the study was 
Before-and-After Studies and Studies of Related Hypotheses
Only one RCT has been specifically designed to test a possible TRIM effect of immunologically active allogeneic WBCs. The Viral Activation Transfusion Study transfused allogeneic RBCs stored for Ͻ2 wks (and thus containing immunologically active WBCs) to the treatment arm. Enrolled HIV-seropositive patients were randomized to receive nonbuffy-coatreduced allogeneic RBCs or RBCs WBCreduced by prestorage filtration. There was no difference between the study arms in the HIV or cytomegalovirus viral load or the length of survival. Median survival was 13.0 months in recipients of WBCreduced RBCs, compared with 20.5 months in recipients of non-WBC-reduced RBCs (p ϭ .12). When adjustment was made for the effects of baseline prognostic factors, a statistically significant (p Ͻ
impugned the theory attributing the TRIM effect to immunologically active allogeneic WBCs (62) .
In the late 1990s, Canada and western European countries implemented universal WBC reduction by means of prestorage filtration, either to enhance overall transfusion safety (Canada and France) or to prevent the transmission of variant Creutzfeldt-Jakob disease by transfusion (United Kingdom, Ireland, and Portugal). Once universal WBC reduction is implemented, the opportunity to conduct RCTs to establish adverse TRIM effects is removed. It is, however, possible to compare the risk of infection in recipients of non-WBC-reduced RBCs before implementation of WBC reduction with the risk of infection in recipients of WBCreduced RBCs after implementation of WBC reduction. Such "before-and-after" studies are observational, and-as such-they cannot establish causal relationships.
Five before-and-after studies have reported data on the risk of postoperative infection of patients having vascular (63), orthopedic or cardiac (64), cardiac (65), or cardiac, orthopedic, or intensive care unit (66) surgery or neonatal transfusion (67) . None of the five studies showed a reduction in the risk of infection after WBC reduction was introduced. When the unadjusted results of the studies were combined in a meta-analysis (68), there was an association of WBC reduction with a decreased risk of postoperative infection (summary OR, 0.93; 95% CI, 0.88 -0.99; p Ͻ .05). Three studies (64, 66, 67) had reported multivariate analyses, andwhen these adjusted results were integrated in the meta-analysis (68)-no effect of WBC reduction on postoperative infection was detected across the three studies (summary OR, 0.94; 95% CI, 0.85-1.04; p Ͼ .05).
In 1998, an association between WBCcontaining ABT and increased mortality in cardiac surgery was reported from the RCT of van de Watering et al. (6) . Those authors (6) postulated that ABT may predispose to multiple organ failure that may predispose to mortality (and/or infection), but they could not show an association of ABT with multiple-organ failure in two subsequent RCTs (8, 32) . After universal WBC reduction was implemented, five before-and-after studies (63, 64, 66, 67, 69) reported data on mortality. A meta-analysis of these five observational studies did not find a reduction in mortality after universal WBC reduction was introduced (68) . However, a metaanalysis (70) of 11 of the RCTs shown in Figure 1 that had reported data on mortality (4 -6, 8, 29 -32, 41, 43, 44) and of the study of Dzik et al. (71) found an association between ABT and mortality in the subgroups of studies transfusing prestorage-filtered RBCs to the control arm or conducted in the setting of cardiac surgery; there was no association between ABT and mortality across all 12 RCTs that were available at that time. It remains to be seen if the associations observed in these two subgroup analyses (70) will persist when the results of the recent RCTs (33, 47) are integrated with the findings of the previous studies.
Dzik et al. (71) enrolled all patients transfused at their hospital, regardless of diagnosis, in an RCT evaluating the effects of prestorage WBC reduction on inhospital mortality, length of hospitalization, and total hospital costs. No deleterious effect of transfusion of nonbuffy-coat-reduced allogeneic RBCs was observed in this population of 2,780 patients. Postoperative bacterial infection was not targeted as an end point, but antibiotic usage was studied as a surrogate for bacterial infection. Antibiotic usage was tabulated in three different ways, and there were no significant differences between the study arms in any comparison. The mean (ϮSD) number of days on antibiotics following transfusion was 9.5 (Ϯ18.6) in recipients of nonbuffy coatreduced RBCs and 9.2 (Ϯ17.4) in recipients of WBC-reduced RBCs (p ϭ .42). In-hospital mortality rate was 8.5% in the former arm and 9.0% in the latter arm (p ϭ .64).
Nathans et al. (72) just reported an RCT assessing the effect of nonbuffy-coatreduced ABT on infection in patients receiving large-volume RBC transfusions for hemorrhage resulting from trauma. Unlike the earlier RCTs that had randomized patients at the time of admission to the hospital, this RCT randomized subjects at the time of type and cross-match (i.e., when blood for transfusion was requested). Furthermore, this RCT used stratified randomization based on age and mechanism of injury. Enrolled patients received non-WBC-reduced or WBCreduced allogeneic RBCs that were Ͻ25 days old. Thirty-seven percent of recipients of nonbuffy-coat-reduced RBCs, as compared with 33% of recipients of WBCreduced RBCs, developed infection (p Ͼ .05); 12% and 11% of these patients, respectively, developed pneumonia (p Ͼ .05). Moreover, there was no effect of nonbuffy-coat-reduced RBCs that were Ͻ25 days old on mortality, median length of hospitalization, length of mechanical ventilation, or multiple organ failure.
CONCLUSIONS
No overwhelming clinical evidence has been presented to establish the existence of an adverse TRIM effect that relates ABT to postoperative infection in general or to postoperative pneumonia in particular. The possibility of a TRIM effect outside the perioperative setting has not, hitherto, been adequately studied, as the 16 available RCTs (3-8, 29 -33, 41-44, 47) enrolled patients transfused perioperatively. Only three more RCTs have been reported, one enrolling all hospitalized patients (71), one enrolling HIVseropositive patients (62) , and one enrolling trauma patients (72) . None of these studies (62, 71, 72) observed any benefit from prestorage WBC reduction.
RCTs transfusing nonbuffy-coat-reduced RBCs to the treatment arm perioperatively (3, 7, 31, 33, 47) may have left open the possibility that allogeneic WBCs and/or WBC-derived soluble mediators exercise TRIM effects that potentially lead to postoperative infection (40) . It remains to be seen whether the effect of nonbuffy-coat-reduced RBCs that was evident previously (40) will persist when the results of all RCTs that are available today (3, 7, 31, 33, 47) are subjected to formal meta-analysis. It will be possible to conduct such an analysis when findings from the latest RCT (47) based on an intention-to-treat analysis are reported. The association of allogeneic plasma with TRIM has been studied inadequately, but the findings of the available studies (31, 51) have nonetheless been negative.
Three types of studies have not hitherto supported the existence of a TRIM effect that results in an increased risk of postoperative infection in association with ABT. These are a) RCTs comparing recipients of buffy-coat-reduced and prestorage-filtered WBC-reduced allogeneic RBCs (6, 8, 29 -32) ; b) RCTs comparing recipients of allogeneic and autologous RBCs or whole blood (4, (41) (42) (43) (44) ; and c) observational studies comparing patients transfused before and after im-plementation of WBC reduction (63) (64) (65) (66) (67) . In all three cases, when all available studies were considered together in a metaanalysis, an adverse TRIM effect was not detected (40, 45, 68) . Thus, most of the evidence supporting a TRIM effect that manifests itself as an association between ABT and postoperative infection comes from earlier observational studies (48) that may not have adequately adjusted for the effects of confounding factors, especially physiologic severity of underlying illness and risk factors for postoperative infection at specific sites (11, 12) .
Two recent meta-analyses (73, 74) of the same RCTs that compared recipients of non-WBC-reduced with WBC-reduced allogeneic RBCs and were discussed here (3, 5-8, 29 -33) have concluded that the totality of the evidence from such RCTs shows that non-WBC-reduced ABT is associated with postoperative infection. The reasons for the different conclusions of the previous meta-analysis (40) and the recent overviews (73, 74) are two-fold: 1) the recent meta-analyses integrated the findings of all ten RCTs (3, 5-8, 29 -33) , despite the fact that the hypothesis of homogeneity (46) was rejected across the studies; and 2) the recent meta-analyses integrated the results from ten observational comparisons that included only the transfused patients from these studies. In contrast, the previous metaanalysis: 1) had not calculated a summary OR across all available studies, because the condition of homogeneity was violated; and 2) had integrated only results from experimental, intention-to-treat comparisons across subsets of homogeneous studies.
As demonstrated in the analysis of Fergusson et al. (74) , comparisons including or excluding the non-transfused subjects (i.e., experimental or observational comparisons, respectively) produced the same overall conclusions when homogeneous subsets of studies were analyzed; the conclusions regarding such subsets were the same as in the previous meta-analysis (40) . Therefore, the main reason why the results of the recent overviews (73, 74) differ from those of the previous meta-analysis (40) is that the recent reports proceeded to integrate all available RCTs, despite the fact that the condition of homogeneity was violated across these studies. The underlying assumption in combining individual study results in a meta-analysis is that their differences are due only to chance, so that all available results reflect the same, "true" effect (46, 75, 76) . Thus, RCTs should be integrated only if the variation in their results is sufficiently modest to be attributed to chance, that is, only when the hypothesis of homogeneity is not rejected.
New data continue to appear (77) (78) (79) (80) , and the controversy over the purported deleterious TRIM effects continues to persist (81) (82) (83) . Because technology that can effectively remove WBCs from RBC and platelet concentrates is available, the controversy regarding the existence of adverse TRIM effects has become inextricably linked to the controversy about the appropriateness of introducing universal prestorage WBC reduction (34 -39) . Because the other adverse effects of transfused WBCs affect specific categories of patients, they can be prevented by means of selective WBC reduction of the components destined for transfusion to those specific categories of patients. In contrast, as all patients are presumably vulnerable to TRIM effects, abrogation of the purported TRIM effects is the best argument for implementing universal WBC reduction of all transfused cellular blood components.
As selective WBC reduction is currently practiced in the United States, results of future studies should be carefully monitored, and conclusions that reflect the totality of the evidence should be reevaluated as new findings become available. Whether adverse clinical TRIM effects truly exist and-in the event that they do-whether they are mediated by allogeneic WBCs and abrogated by WBC reduction are important policy questions (36) as the United States and many other countries continue to consider the appropriateness of implementing universal WBC reduction.
